Sign In
Buy VERU
$2.77
+0.440 (+18.88%)
At Close: Aug 10, 2026
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?
01:01pm, Thursday, 23'rd Jan 2025
Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
08:30am, Tuesday, 31'st Dec 2024
MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates
08:01pm, Monday, 16'th Dec 2024
Veru Inc. (VERU) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.
Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders
08:30am, Tuesday, 26'th Nov 2024
MIAMI, FL, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
MIAMI, FL, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
MIAMI, FL, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
MIAMI, FL, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Present at the 2024 Cantor Global Healthcare Conference
08:30am, Wednesday, 11'th Sep 2024
MIAMI, FL, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high qualit
Veru Inc. (VERU) Q3 2024 Earnings Call Transcript
08:39am, Saturday, 10'th Aug 2024
Veru Inc. (NASDAQ:VERU ) Q3 2024 Results Conference Call August 8, 2024 8:00 AM ET Company Participants Sam Fisch - Investor Relations & Corporate Communications Mitchell Steiner - Chief Executive Off
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
08:46am, Thursday, 08'th Aug 2024
Veru Inc. (VERU) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.13 per share a year ago.
--Phase 2b QUALITY study of enobosarm in combination with semaglutide (Wegovy®*) exceeds targeted full enrollment of >150 patients-- --Topline data for primary endpoint of lean body mass expected Jan
Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024
08:30am, Thursday, 01'st Aug 2024
MIAMI, FL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Participate in the BTIG Virtual Biotechnology Conference
08:30am, Monday, 29'th Jul 2024
MIAMI, FL, July 29, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism
08:30am, Tuesday, 02'nd Jul 2024
MIAMI, FL, July 02, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
MIAMI, FL, June 24, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality
